Skip to main
PTGX

Protagonist Therapeutics (PTGX) Stock Forecast & Price Target

Protagonist Therapeutics (PTGX) Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 31%
Buy 62%
Hold 8%
Sell 0%
Strong Sell 0%

Bulls say

Protagonist Therapeutics Inc. is demonstrating encouraging clinical results for its drug candidate, icotrokinra, with significant improvements in clinical response and endoscopic outcomes, notably a 31.7% clinical remission rate at 28 weeks in the 400mg cohort. The company anticipates strong growth potential driven by icotrokinra's efficacy in addressing unmet medical needs, particularly in the milder segment market following Otezla's exit, reinforced by a robust safety profile. Additionally, Protagonist's solid business development track record and the expected momentum in its pipeline leading to key catalysts in 2025 support a favorable long-term outlook for the stock.

Bears say

The financial outlook for Protagonist Therapeutics appears negative due to multiple risk factors inherent in the biopharmaceutical industry, including the potential for unexpected safety concerns during clinical trials, which could hinder product development and approval. Additionally, there is significant concern regarding the strategic decisions of partners to continue developing the drug Icotrokinra due to competitive pressures, alongside increasing regulatory scrutiny and pricing risks in the market. Furthermore, the company faces the prospect of future cash needs that may lead to dilution, adding another layer of financial uncertainty to its operations.

Protagonist Therapeutics (PTGX) has been analyzed by 13 analysts, with a consensus rating of Buy. 31% of analysts recommend a Strong Buy, 62% recommend Buy, 8% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Protagonist Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Protagonist Therapeutics (PTGX) Forecast

Analysts have given Protagonist Therapeutics (PTGX) a Buy based on their latest research and market trends.

According to 13 analysts, Protagonist Therapeutics (PTGX) has a Buy consensus rating as of Dec 24, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $81.15, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $81.15, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Protagonist Therapeutics (PTGX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.